Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.
Two posters presented at the CHEST 2024 annual meeting last week in Boston, Massachusetts, revealed that only 18% of eligible patients hospitalized with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) participated in pulmonary rehabilitation (PR) post-discharge, with ineligibility significantly limiting participation.
The first poster emphasized that health care providers and patients should be properly educated on PR referral and participation to ensure appropriate post-hospitalization care for those with AECOPD.1
The American Thoracic Society’s 2023 guidelines recommended that patients participate in PR within 3 weeks of admission for AECOPD.2 Despite this, previous research found that only 1.9% participated in PR within 6 months of their index hospitalization.3
Consequently, the researchers conducted a quality improvement initiative to assess current trends in PR enrollment after AECOPD hospitalization at Baystate Medical Center, a tertiary medical center in Springfield, Massachusetts.1 They aimed to improve PR uptake by understanding barriers to referral and participation.
The researchers conducted a retrospective analysis of patients admitted with AECOPD between December 1, 2022, and December 1, 2023; they identified eligible patients using the International Classification of Diseases, 10th Revision (ICD-10) code J.441. Additionally, the researchers identified those evaluated at the Baystate Medical Center pulmonary rehab facilities using the Current Procedural Terminology (CPT) code 94625.
Through this process, 1255 AECOPD encounters were identified, but 770 patients qualified for the final analysis. Of these patients, 140 (18%) were evaluated at the pulmonary rehab facilities. PR participants were older, with a mean (SD) age of 71.1 (8.6) years vs non-participants, who were 64.5 (10.7) years old.
Among both participants and non-participants, the hospital length of stay was highly variable, with a mean of 5.2 days. Additionally, the researchers found that only 3 patients hospitalized for over 7 days were seen at PR.
At discharge, 58% of the cohort required additional services. More specifically, 36.5% required visiting nurses and physical therapists, while 21% were discharged to nursing facilities. Lastly, the researchers emphasized that 197 patients had recurrent admissions within the study period, accounting for 46.4% of total AECOPD admissions; only 8 were evaluated at PR.
“...emphasis on PR referral and enrollment in those with recurrent admissions or pronged hospital stays might lead to a decrease in the health care burden,” the authors concluded. “More research is needed to elucidate barriers to referral and participation in PR.”
Building on these findings, the second poster explored eligibility and ineligibility categories in PR post-discharge.4 Although multiple factors likely influence post-discharge PR participation, the researchers claimed that patient PR eligibility has received relatively little attention.
Therefore, 3 physician or advanced practice registered nurse (APRN) investigators with clinical pulmonary experience performed independent hospital data reviews of all patients discharged with codes indicating acute respiratory failure or a COPD exacerbation over 1 year, beginning on June 1, 2022; they performed the reviews at 2 hospitals, 1 in a suburban setting and the other in an urban setting.
The investigators made decisions regarding eligibility/ineligibility based only on medical record data and the interpretation of selection criteria from a joint American Thoracic Society and European Respiratory statement on PR.5 Therefore, patients were deemed potentially eligible for outpatient PR if 2 of the 3 reviewers agreed that a correct COPD diagnosis leading to hospitalization was made and the patient met all PR inclusion criteria and no exclusion criteria4; full concordance was considered if all 3 reviewers agreed.
The researchers identified 360 eligible patients, whose mean age was 71 (12) years. Most patients were female (53%) and White (76%); also, 40% were of lower socioeconomic status, meaning they had Medicaid or no insurance. Full concordance on patient PR eligibility/ineligibility was 73%.
Based on the agreement of 2 of 3 investigators, the reviewers considered only 38% of patients eligible for PR. The category that contributed most to ineligibility was having an illness or frailty either too great or putting the patient at excessive risk for participation (45%).
Another was having cognitive, psychiatric, or substance abuse issues that would preclude full PR participation (24%). Other categories that contributed to patient ineligibility were incorrect COPD diagnoses leading to hospitalization (19%), being institutionalized post-discharge (9%), and a language barrier (4%).
“Reported percentage uptake would likely increase if only eligible patients were analyzed,” the authors concluded. “...A larger prospective study should be considered.”
Overall, both posters underscore the significant underutilization of post-discharge PR among patients hospitalized with AECOPD and call for strategies to increase uptake by targeting eligibility criteria and participation barriers.
References
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More